May 14, 2026 | Press Releases
First Reporting Quarter as Valion Bio Marked by Continued Advancement of the Entolimod Platform, Broader Government Engagement, and Continued Integration of Velocity BioworksConference Call to be Held Today at 1:30 PM PT / 4:30 PM ETSAN ANTONIO , May 14, 2026...
May 11, 2026 | Press Releases
SAN ANTONIO, Texas, May 11, 2026 /PRNewswire/ — Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company developing Entolimod™ for Acute Radiation Syndrome (ARS) and oncology supportive care, today...
May 6, 2026 | Press Releases
Senator John Cornyn recognizes facility’s role in advancing radiation countermeasures for cancer patients and U.S. warfighters; Mayor Gina Ortiz Jones, Office of Senator Cornyn, and Velocity Bioworks leadership join Valion Bio at ribbon cutting ceremonySAN...
May 4, 2026 | Press Releases
Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experience Joins Leadership TeamSAN ANTONIO, May 4, 2026 /PRNewswire/ — Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage...
Apr 28, 2026 | Press Releases
Company Presented Entolimod™ from its TLR5 Platform to the Deputy Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense ProgramsSAN ANTONIO, April 28, 2026 /PRNewswire/ — Valion Bio, Inc. (formerly Tivic Health Systems, Inc.)...